Change search
ReferencesLink to record
Permanent link

Direct link
Effect of selective serotonin reuptake inhibitors use on endocrine therapy adherence and breast cancer mortality: a population-based study
Uppsala University, Disciplinary Domain of Medicine and Pharmacy, Medicinska och farmaceutiska vetenskapsområdet, centrumbildningar mm, Centrum för klinisk forskning i Sörmland (CKFD).
Kings Coll London, Sch Med, Div Canc Studies, Canc Epidemiol Unit, London, England..
Kings Coll London, Inst Pharmaceut Sci, London SE1 9NH, England..
Karolinska Inst, Karolinska Univ Hosp, Dept Mol Med & Surg, Stockholm, Sweden..
Show others and affiliations
2016 (English)In: Breast Cancer Research and Treatment, ISSN 0167-6806, E-ISSN 1573-7217, Vol. 159, no 2, 293-303 p.Article in journal (Refereed) Published
Abstract [en]

The purpose of the study was to investigate whether the concomitant use of selective serotonin reuptake inhibitors (SSRI) with tamoxifen influences the risk of death due to breast cancer, and we also investigated the association between SSRI use and adherence to oral endocrine therapy (ET). We analyzed data from BCBaSe Sweden, which is a database created by the data linkage of Registries from three different regions of Sweden. To investigate the association between ET adherence and SSRI use, we included all women who were diagnosed with non-distant metastatic ER-positive invasive breast cancer from July 2007 to July 2011 and had at least one dispensed prescription of oral tamoxifen or aromatase inhibitor. To investigate the role of concurrent administration of SSRI and tamoxifen on breast cancer prognosis, we performed a nested case-control study. In the adherence cohort, 9104 women were included in the analyses. Women who received SSRI, either before or after breast cancer diagnosis, were at higher risk for low adherence to ET. However, when the overlapping period between SSRI use and ET was > 50 %, no excess risk for low adherence was observed. Non-adherence (< 80 %) to ET was significantly associated with worse breast cancer survival (OR 4.07; 95 % CI 3.27-5.06). In the case-control study, 445 cases and 11125 controls were included. The concomitant administration of SSRI and tamoxifen did not influence breast cancer survival, neither in short-term (OR 1.41; 95 % CI 0.74-2.68) nor in long-term SSRI users (OR 0.85; 95 % CI 0.35-2.08). Concomitant SSRI and tamoxifen use does not seem to increase risk for death due to breast cancer. Given the positive association between continuing antidepressive pharmacotherapy for a longer period of time and adherence to ET, it is essential to capture and treat depression in breast cancer patients to secure adherence to ET.

Place, publisher, year, edition, pages
2016. Vol. 159, no 2, 293-303 p.
Keyword [en]
Breast cancer, SSRI, Adherence, Endocrine therapy, Prognosis, Tamoxifen
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-305541DOI: 10.1007/s10549-016-3928-3ISI: 000382991500009PubMedID: 27492739OAI: diva2:1040302
Available from: 2016-10-27 Created: 2016-10-19 Last updated: 2016-10-27Bibliographically approved

Open Access in DiVA

fulltext(495 kB)14 downloads
File information
File name FULLTEXT01.pdfFile size 495 kBChecksum SHA-512
Type fulltextMimetype application/pdf

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Valachis, Antonis
By organisation
Centrum för klinisk forskning i Sörmland (CKFD)
In the same journal
Breast Cancer Research and Treatment
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
Total: 14 downloads
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 109 hits
ReferencesLink to record
Permanent link

Direct link